-
-
-
-
-
-
-
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
-
-
-
-
-
-
-
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Po
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) Appoints Daniel Swisher to its Board
-
-
-
-
-
-
-
After-Hours Stock Movers 03/22: (BLFS) (CHMA) (PTGX) Higher; (IONS) (RAVN) (QS) Lower (more...)
-
-
-
-
1,177,050 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

